Israel has become known for its innovation and technology. The company currently has the highest numbers of startups per capita, according to research. As one the major players in the technical innovation, the company has been instrumental in taking medical research to another level. Of particular importance is its contribution to Alzheimer’s research. Recently, the country recognized Prof. Marta Weinstock-Rosin for her role in creating the first FDA-approved medication for treating Alzheimer’s in its earliest stages.
Made in Israel, Rivastigmine (Excelon) and Progress
An estimated 4 billion adults in the U.S. have been affected by Alzheimer’s disease. Rivastigmine (Exelon) is one of the most exciting developments in treating Alzheimer’s disease Israeli researchers have been awarded the prestigious Israel Prize for Medicine for their involvement in developing the medication. Chief developer, Prof. Marta Weinstock-Rosin, led research and development efforts and has been recognized for the significant role she played in developing the drug.
Making Strides in Treating Alzheimer’s Disease
Rivastigmine, which is marketed as Exelon, has emerged as an important drug critical to the medical community for its role in treating Alzheimer’s disease and Parkinson’s disease. The drug, classified as an inhibitor, is used to target the acetylcholinesterase to prevent the destruction of neurotransmitters that can affect the chemical activity in the brain. In reducing the Acetylcholine levels in the brain by blocking them, it slows the progression of the Alzheimer’s disease. It can improve thinking and cognitive functioning in individuals suffering from early onset Alzheimer’s disease.
Who Is It For?
It is typically prescribed to patients with mild to moderate Alzheimer’s disease. Although drugs like these do not prevent the disease, they can delay symptoms and slow the progression of the condition. Patients in these categories are treated with medications like doneprezil, galantamine and rivastigmine. While scientists continue to make encouraging progress toward understanding the disease, they recognize that much work lies ahead. It isn’t uncommon for patients to respond better to one cholinesterase inhibitors than another. Some patients experience fewer side effects when on a different medication in the same class.
Advantages of Taking the Medication
Rivastigmine (Exelon) has been proven effective in managing three significant domains of the Alzheimer’s condition. Patients on the medication are likely to see improvements in cognition, behaviors and their ability to carry out normal everyday routines. Families can be encouraged in knowing that the powerful drug can delay the progression of the disease by five years. The drug is also beneficial to the U.S. economy in helping taxpayers save an estimated $50 billion in U.S. healthcare costs annually, cutting in half patient sending previously allocated toward treating Alzheimer’s.
Recognizing Advancements in Alzheimer’s Medication
The award was presented at the annual Israel Independence Day ceremony. The prime minister recognizes excellence in medical innovation at the state ceremony each year. The Novartis Exelon Patch is the very first FDA-approved skin patch for treating Alzheimer’s disease patients. To date, the medication has sold an impressive $1 billion in 2012 and has been approved for marketing in over 70 countries.
Her Ongoing Commitment to Alzheimer’s Research
Prof. Marta Weinstock-Rosin continues to work faithfully toward the development of cutting edge medications that are capable of treating the condition. Currently, she is working on Ladostigil, a mild cognitive impairment (MCI) during the earliest stages of Alzheimer’s disease. Her passion and commitment to Alzheimer’s research will undoubtedly lead to further advancements in medicine for Alzheimer’s disease. The medical community celebrates the accomplishments of dedicated researchers like Prof. Marta Weinstock-Rosin for world class medications made in Israel. Future trends suggest that as advancements continue to be made, more access to prescription medication will become available online to continue empowering consumers.186